CAL
HUMA icon

Capital Advisors Ltd’s Humacyte HUMA Stock Holding History

Capital Advisors Ltd’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Hold
2,000
– – ﹤0.01% 1122
2026
Q1 		$1K Hold
2,000
– – ﹤0.01% 1230
2025
Q4 		$2K Hold
2,000
– – ﹤0.01% 1085
2025
Q3 		$3K Hold
2,000
– – ﹤0.01% 1005
2025
Q2 		$4K Buy
+2,000
New +$3.84K ﹤0.01% 964

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capital Advisors Ltd's HUMA Position: Q2 2026 in Review

Capital Advisors Ltd held its Humacyte (HUMA) position steady in Q2 2026 at 2,000 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1122.

Capital Advisors Ltd first reported a position in HUMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $4K in Q2 2025. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Capital Advisors Ltd held 2,000 shares of Humacyte worth $2K as of Q2 2026.
  • Capital Advisors Ltd left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1122 holding.
  • Capital Advisors Ltd first reported a position in Humacyte in Q2 2025 and has held it in 5 quarters since.
  • Capital Advisors Ltd's Humacyte position peaked at $4K in Q2 2025.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.